Keyword: Drug reform

161 results found
A legislative update on provincial biosimilar policies

When the City of Toronto switched benefits plan insurers in 2017, it changed its coverage for biologics and biosimilars. Under its previous plan, the City reimbursed employees for the drugs their doctors recommended and prescribed; now, it follows its new insurer’s mandatory biosimilars policy, while grandfathering any plan member who was already taking a biologic […]

Economic statement includes new rules for employee stock options

In Monday’s fall economic statement, the federal government proposed changes to employee stock option rules and offered additional support for essential workers. The statement provided an overview of the government’s approach to combating the ongoing coronavirus pandemic, while offering details on additional measures moving forward. The changes to employee stock option tax rules include an annual […]

  • By: Staff
  • December 1, 2020 April 28, 2021
  • 10:30
CLHIA’s Ontario budget submission highlights drug access, inflexible pension plans

In its 2020 budget submission to the Ontario government, the Canadian Life and Health Insurance Association is highlighting a lack of access to affordable prescription drugs and inflexible pension plans. With respect to prescription drugs, the CLHIA noted it supports the federal Patented Medicine Prices Review Board reforms, which were introduced on Friday. “It is crucial that the […]

  • By: Staff
  • October 26, 2020 October 26, 2020
  • 15:15
PMPRB publishes new guidelines on drug pricing in Canada

The Patented Medicine Prices Review Board published its new guidelines on Friday. The guidelines, which will take effect on Jan. 1, 2021, aim to modernize Canada’s pricing framework for patented medicines. They explain the steps that will typically be taken by the PMPRB’s staff in assessing whether a patented medicine appears to be priced excessively in Canada. The […]

  • By: Staff
  • October 23, 2020 October 23, 2020
  • 15:15

With employers and employees still suffering through the limbo of the coronavirus pandemic, Wednesday’s throne speech clarified how the federal government plans to continue to support Canadians. In her speech, Governor General Julie Payette said the Canada Emergency Wage Subsidy will be extended into 2021. She also said the government intends to shift away from emergency benefits […]

Over the past four years, total drug costs adjudicated by HBM+ have risen from about $1.2 billion to $1.5 billion, while the number of claimants has increased from 1.7 million to more than two million. The inaugural drug trends and strategic insights report by the health benefits manager, a division of Green Shield Canada, examined drug […]

  • By: Staff
  • September 18, 2020 November 17, 2020
  • 15:00
Rare disease drugs strategy, standard coverage in CLHIA’s 2020 budget wish list

The Canadian Life and Health Insurance Association is recommending the federal government develop a strategy for high-cost drugs for rare diseases, potentially by harmonizing catastrophic drug coverage across the country. In its August federal budget submission to the standing committee on finance, the association noted specialty drugs, including those for chronic and rare disease, made up just two […]

  • By: Staff
  • August 12, 2020 November 12, 2020
  • 15:00
PMPRB changes within scope of Patent Act, rules federal court in judicial review

The Federal Court has upheld reforms to the Patented Medicines Pricing Review Board that updated the board’s reference countries for drug pricing and required it to review three new economic factors when determining whether patented medicines are excessively priced. The court ruled against an argument by Innovative Medicines Canada and 16 pharmaceutical companies in their […]

Benefits plan members, sponsors cite low levels of knowledge on pharmacare: survey

While 67 per cent of Canadian plan members described their level of knowledge about a possible national pharmacare program as low or medium, 27 per cent said they don’t know anything at all about it, according to the 2020 Sanofi Canada health-care survey. Among plan sponsor respondents, 73 per cent described their level of knowledge […]

  • By: Staff
  • June 30, 2020 November 11, 2020
  • 09:15

As reported earlier this month, the Patented Medicine Prices Review Board has published a new draft of its guidelines and launched a 30-day written consultation period. While the law and regulations have already been passed, the implementation has been delayed from July 1, 2020 to Jan. 1, 2021. The new draft guidelines are in response […]